Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. - Wikidata - wikimedia - TriplyDB

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.

http://www.wikidata.org/entity/Q36924418

about

Cytotoxic and targeted therapy for hereditary cancers Targeted Therapies in Triple-Negative Breast Cancer Liver Metastasis of a Triple-Negative Breast Cancer and Complete Remission for 5 Years After Treatment With Combined Bevacizumab/Paclitaxel/Carboplatin: Case Report and Review of the Literature TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†Realizing the promise of cancer predisposition genes.Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40 Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status Cancer suppression by the chromosome custodians, BRCA1 and BRCA2.Mainstreaming genetic testing of cancer predisposition genes.Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.Familial breast cancer - targeted therapy in secondary and tertiary prevention Have we given up on a cure for ovarian cancer?Pit-1 inhibits BRCA1 and sensitizes human breast tumors to cisplatin and vitamin D treatment.Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer Systemic treatment for hereditary cancers: a 2012 update.Cisplatin induces differentiation of breast cancer cells Development and clinical application of an integrative genomic approach to personalized cancer therapy A cost analysis of a cancer genetic service model in the UK Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.dbCPG: A web resource for cancer predisposition genes.Gene expression analysis in ovarian cancer - faults and hints from DNA microarray study.Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status.Poorer breast cancer survival outcomes in males than females might be attributable to tumor subtype.Opportunities and hurdles in the treatment of BRCA1-related breast cancer.BRCA1 and BRCA2 - update and implications on the genetics of breast cancer: a clinical perspective.Primary therapy in breast cancer: what have we learned from landmark trials?Opportunities and challenges of next-generation DNA sequencing for breast units.Assessing the role of platinum agents in aggressive breast cancers.Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers.Neoadjuvant Chemotherapy In Triple-Negative Breast Cancer: A Multicentric Retrospective Observational Study In Real-Life Setting.Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant.Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.Biology and Management of Patients With Triple-Negative Breast Cancer.The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.

P2860

Q26739366-2296145F-A7CA-4137-A586-5502C928FCE0 Q26777736-7B8DF791-D68A-46F9-BEA6-61121DDE2102 Q26779880-AC51787E-B451-447F-89FC-9F46C75F3553 Q27853147-00F1238D-8AFD-4E6C-85C7-149AFEF9482F Q27853293-A1159EE8-D51A-44F9-BBBD-826CB8DB78B5 Q30317067-E4BBF775-3F3B-4F09-BD89-2FA1DA49E99C Q30743260-769A239D-3F9C-4DCA-93D3-2149C7323941 Q33414349-7920DF8F-79C3-4A7D-ACB3-29FCFAF9FC00 Q33416887-D0014170-1497-45F5-A1FE-854C2C55C99D Q33440778-6D3E4D75-F850-422F-8532-647E02B76963 Q34038170-6A04362A-D21F-4655-BC62-F0BD9BF7BA91 Q34412496-F729C5F6-220F-4B7F-B640-D13D6B9EF28B Q35034822-BFD722B4-289C-4D76-96DF-684A5D256D87 Q35374807-B75BA54E-03C8-4971-BC5C-B8B2B2AE1A79 Q35399626-16D9EFD4-499F-47B5-A5AF-EA81B160DE2C Q35714581-95233D3F-6EA6-4623-8924-F696DDE487AA Q35987385-97E5ED95-A38E-4BE8-B708-6C0859993B80 Q36494555-4C1F2C74-4B52-4457-B0BF-5BE2AC78337B Q36755366-32C011F1-6CD1-409E-9061-30D049D9D407 Q36893886-BCC20B88-3B02-41ED-A227-FA6255E65D30 Q36954557-2ACB10BF-5C1C-4FBA-A1A9-716513A3EBCD Q37124110-27E69A46-A88D-46AC-AF73-1857CEBAA0C3 Q37128739-ACAD2A5A-1F05-437C-A3FC-A3EC6D143CDC Q37437305-11781C68-D887-4E53-9EB8-D29DF561052F Q37522638-BCA39700-4162-4034-931F-5C6C4FDB9391 Q37578483-552FADE3-F380-4627-9695-97B2ECB46783 Q37583113-2122C1FC-B8AE-4A0F-9D1D-AF6139065FCA Q37699467-8BFB752F-F168-4F72-9192-13C5ECB2353E Q38129725-855F9112-87CB-4873-82D1-C2D1E442A036 Q38151730-73FACDC7-2BB4-46FD-9251-E95C24D9EB71 Q38155673-AE14861D-4620-4516-914F-53424D59CDF0 Q38200002-B3AD3A54-C66B-4BC9-BDF0-F283E73B3A66 Q38349378-BF7FD9D7-4197-4F22-89A9-7D378FCC41F3 Q38389226-DFFFEE03-6EF1-4BAF-82AC-493CF8DCEA0E Q38677841-88A15EA7-15BD-4F09-9AD8-3F2709ED3BA7 Q38760757-098D9D3F-6B72-4BB4-B191-CE4A6B77D712 Q38806371-5765D4AB-8505-4D3A-8299-CF9ADBE2C0F2 Q38811820-9F8FEA94-2140-4C8E-B9C2-1AF4199B2D4E Q38893074-52637E10-03D1-4393-9B0E-0D58833A09E3 Q39190147-B9ECE3AA-4A48-4BC0-B190-21FF490A31E3

P2860

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.

http://www.wikidata.org/entity/Q36924418

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Results of a phase II open-lab ...... tive metastatic breast cancer.

@en

type

label

Results of a phase II open-lab ...... tive metastatic breast cancer.

@en

prefLabel

Results of a phase II open-lab ...... tive metastatic breast cancer.

@en

P1433

Q36924418-C10FCA4B-8EB9-4C60-85DA-3F20D7E62222

P1476

Q36924418-1594ED4F-3D0F-459F-B8F4-F35ADD289D9C

P2093

Q36924418-15159824-5E1C-43A2-8E20-8FC3E89579AC

Q36924418-2BD13E25-FB00-424D-BA31-4B7CD5180D87

Q36924418-8AF25BFD-6B6B-4941-A00C-142B95A7AA90

Q36924418-B464A89D-99D2-4BC9-ADFE-78477DF36158

Q36924418-BA5843BF-7574-45EA-A56C-C1CB993D4ABC

Q36924418-C422FC9A-487F-4C52-A8F7-35C6A606860E

Q36924418-DDA2C899-D501-47C4-8187-A0C89CAC3F11

Q36924418-E0C9F3B9-C52A-46DE-9F40-06256856521D

P2860

Q36924418-209EED47-2D09-4C96-89D6-4E3AD4B6B575

Q36924418-3F9BBB32-1C65-4AC8-A73F-3B9E4AC9F20D

Q36924418-6111254D-5315-47B3-9049-74BC9A2651DD

Q36924418-6205F73C-8D74-4C51-9AAE-7F8814B0420C

Q36924418-6CC978D5-0067-4A00-8C1E-B0C9BF718AF6

Q36924418-6D166C03-E516-45E3-90C1-6FFB5272345D

Q36924418-7578CD47-8274-4899-9717-FBC5EEBFE174

Q36924418-77399F0C-116C-409D-A873-143AB89844FF

Q36924418-7A95FCF7-C02A-4B23-8D64-7160CCA690C1

Q36924418-834B8394-C962-4AE9-9563-876F9A6B1F29

P2888

Q36924418-79C4C781-DF3C-4444-A4AD-1631841F29B1

P304

Q36924418-A533E2FE-9BD2-4986-B4BD-924B9E6E87F2

P31

Q36924418-B742ED43-8129-4946-A003-0EF195093088

P356

Q36924418-D7FE713B-7464-4564-951D-758ED309B9B5

P433

Q36924418-10A2BAA5-7DBB-4E40-AA7E-E5B6C9F6DEAE

P478

Q36924418-7BD1C360-EB3C-4B15-8041-878B3378B676

P50

Q36924418-047CEEC0-8F0E-4602-8638-0211CD88CB6F

Q36924418-0ADFD6F9-91D8-45FC-8989-FAB0D06E99F1

Q36924418-1160A51A-5526-4A7F-9E12-36E2F241B0C4

Q36924418-D2457746-1BF0-45D9-AADA-7BA9195B51E3

P577

Q36924418-FC8E65E4-B47C-4550-841A-5160900F226A

P5875

Q36924418-B8C6F697-0031-4359-A756-1DD1611F699F

P6179

Q36924418-807461B4-2A30-49E0-9584-BF2565474B00

P698

Q36924418-DD5DDD45-7383-4F46-B843-C756A7D16792

P921

Q36924418-0B729674-74C3-478F-8224-82E29A3B01CF

Q36924418-3D4451DA-C171-4555-A4CD-E1B24B780E15

P932

Q36924418-0F6D852D-1D3C-4E44-9399-4F2FDF106CC1

P356

P1433

Breast Cancer Research

P1476

Results of a phase II open-lab ...... tive metastatic breast cancer.

@en

P2093

Andrea Eisen

http://www.w3.org/2001/XMLSchema#string

Elzbieta Marczyk

http://www.w3.org/2001/XMLSchema#string

Jacek Gronwald

http://www.w3.org/2001/XMLSchema#string

Malgorzata Foszczynska-Kloda

http://www.w3.org/2001/XMLSchema#string

Pawel Blecharz

http://www.w3.org/2001/XMLSchema#string

Rebecca Dent

http://www.w3.org/2001/XMLSchema#string

Robert Chrzan

http://www.w3.org/2001/XMLSchema#string

Tomasz Huzarski

http://www.w3.org/2001/XMLSchema#string

P2860

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.

A high proportion of founder BRCA1 mutations in Polish breast cancer families.

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.

The resurgence of platinum-based cancer chemotherapy.

The role of BRCA1 in the cellular response to chemotherapy.

Targeting the DNA repair defect of BRCA tumours.

P2888

P304

R110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR3231

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Cezary Cybulski

Steven A. Narod

P577

2012-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229433999

http://www.w3.org/2001/XMLSchema#string

P6179

1026844460

http://www.w3.org/2001/XMLSchema#string

P698

22817698

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3680929

http://www.w3.org/2001/XMLSchema#string